CONTACT US
Home > Inhibitors/Agonists>Organic Building Blocks> > Riamilovir
123606-06-4-Riamilovir Riamilovir

Riamilovir

For research use only. Not for therapeutic Use.

  • CAT Number: I035568
  • CAS Number: 123606-06-4
  • Molecular Formula: C5H4N6O3S
  • Molecular Weight: 228.19
  • Purity: 98%
Inquiry Now
Related Small Molecules: 5-Hydroxy-2-nitrobenzyl alcohol     GDC-0941 Dimethanesulfonate     INF4E    

Riamilovir, also known as Triazavirin, is an antiviral drug candidate. Tiazavirin is a broad-spectrum antiviral drug developed in Russia. It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs. It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity. However triazavirin has also been found to have antiviral activity against a number of other viruses including Tick-borne encephalitis virus, and Forest-Spring Encephalitis virus, and is also being investigated for potential application against Lassa fever and Ebola virus disease. In February 2020, testing of triazavirin was started against SARS-CoV-2.


Catalog Number I035568
CAS Number 123606-06-4
Synonyms

Riamilovir; Triazavirin; TZV;

Molecular Formula C5H4N6O3S
Purity 98%
Solubility Soluble in DMSO
Appearance Solid powder
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name 7-(methylsulfanyl)-3-nitro[1,2,4]triazolo[5,1-c][1,2,4]triazin- 4(1H)-one
InChI InChI=1S/C5H4N6O3S/c1-15-5-6-4-8-7-2(11(13)14)3(12)10(4)9-5/h1H3,(H,6,8,9)
InChIKey IDVQGNMSSHPZSJ-UHFFFAOYSA-N
SMILES O=C1N2C(NN=C1[N+]([O-])=O)=NC(SC)=N2
Reference

This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). Do not reply directly to this message
Sent On: Thu Oct 15 14:14:09 2020
Search: Triazavirin
18 selected items
PubMed Results
Items 1-18 of 18 (Display the 18 citations in PubMed)
1: Wu X, Yu K, Wang Y, Xu W, Ma H, Hou Y, Li Y, Cai B, Zhu L, Zhang M, Hu X, Gao J, Wang Y, Qin H, Wang W, Zhao M, Wu X, Zhang Y, Li L, Li K, Du Z, Mol BWJ, Yang B. Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial. Engineering (Beijing). 2020 Sep 8. doi: 10.1016/j.eng.2020.08.011. Epub ahead of print. PMID: 32923016; PMCID: PMC7476906.
2: Wu X, Yu K, Wang Y, Xu W, Ma H, Hou Y, Li Y, Cai B, Zhu L, Zhang M, Hu X, Gao J, Wang Y, Qin H, Zhao M, Zhang Y, Li K, Du Z, Yang B. The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol. Engineering (Beijing). 2020 Jul 3. doi: 10.1016/j.eng.2020.06.011. Epub ahead of print. PMID: 32837750; PMCID: PMC7332434.
3: Shahab S, Sheikhi M. Triazavirin – Potential inhibitor for 2019-nCoV Coronavirus M protease: A DFT study. Curr Mol Med. 2020 May 20. doi: 10.2174/1566524020666200521075848. Epub ahead of print. PMID: 32436829.
4: Zabrodskaya YA, Shvetsov AV, Tsvetkov VB, Egorov VV. A double-edged sword: supramolecular complexes of triazavirine display multicenter binding effects which influence aggregate formation. J Biomol Struct Dyn. 2019 Aug;37(12):3041-3047. doi: 10.1080/07391102.2018.1507837. Epub 2018 Nov 15. PMID: 30073907.
5: Shvetsov AV, Zabrodskaya YA, Nekrasov PA, Egorov VV. Triazavirine supramolecular complexes as modifiers of the peptide oligomeric structure. J Biomol Struct Dyn. 2018 Aug;36(10):2694-2698. doi: 10.1080/07391102.2017.1367329. Epub 2017 Sep 12. PMID: 28828928.
6: Kozhikhova KV, Ivantsova MN, Tokareva MI, Shulepov ID, Tretiyakov AV, Shaidarov LV, Rusinov VL, Mironov MA. Preparation of chitosan-coated liposomes as a novel carrier system for the antiviral drug Triazavirin. Pharm Dev Technol. 2018 Apr;23(4):334-342. doi: 10.1080/10837450.2016.1242624. Epub 2016 Oct 25. PMID: 27681534.
7: Loginova SY, Borisevich SV, Rusinov VL, Ulomsky EN, Charushin VN, Chupakhin ON, Sorokin PV. [Investigation of Therapeutic Efficacy of Triazavirin Against Experimental Forest-Spring Encephalitis on Albino Mice]. Antibiot Khimioter. 2015;60(7-8):11-3. Russian. PMID: 26863736.
8: Loginova SY, Borisevich SV, Rusinov VL, Ulomsky UN, Charushin VN, Chupakhin N, Sorokin PV. [Investigation of Prophylactic Efficacy of Triazavirin Against Experimental Forest- Spring Encephalitis on Albino Mice]. Antibiot Khimioter. 2015;60(5-6):8-11. Russian. PMID: 26852489.
9: Blazhennikova IV, Kurliakova AF, Bykov VN, Geĭbo DS, Nikiforov AS, Stepanov AV, Charushin VN, Chupakhin ON, Kotovskaia SK, Rusinov VL. [Experimental comparative pharmacokinetics of levofloxacin, triazavirin, and related conjugate]. Eksp Klin Farmakol. 2015;78(2):34-8. Russian. PMID: 25898546.
10: Loginova SIa, Borisevich SV, Rusinov VL, Ulomskiĭ UN, Charushin VN, Chupakhin ON. [Investigation of Triazavirin antiviral activity against tick- borne encephalitis pathogen in cell culture]. Antibiot Khimioter. 2014;59(1-2):3-5. Russian. PMID: 25051708.
11: Kiselev OI, Deeva EG, Mel’nikova TI, Kozeletskaia KN, Kiselev AS, Rusinov VL, Charushin VN, Chupakhin ON. [A new antiviral drug Triazavirin: results of phase II clinical trial]. Vopr Virusol. 2012 Nov-Dec;57(6):9-12. Russian. PMID: 23477247.
12: Loginova SIa, Borisevich SV, Rusinov VL, Ulomskiĭ UN, Charushin VN, Chupakhin ON. [Toxicity of triazavirin, a novel Russian antiinfluenza chemotherapeutic]. Antibiot Khimioter. 2012;57(11-12):8-10. Russian. PMID: 23700930.
13: Loginova SIa, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, Charushin VN, Chupakhin ON. [Therapeutic efficacy of Triazavirin, a novel Russian chemotherapeutic, against influenza virus A (H5N1)]. Antibiot Khimioter. 2011;56(1-2):10-2. Russian. PMID: 21780665.
14: Smirnova TD, Danilenko DM, Eropkin MIu, Deeva EG, Kiselev OI. [Influence of rimantadine, ribavirine and triazavirine on influenza A virus replication in human monolayer and lymphoblastoid cell lines]. Antibiot Khimioter. 2011;56(11-12):11-6. Russian. PMID: 22856151.
15: Karpenko I, Deev S, Kiselev O, Charushin V, Rusinov V, Ulomsky E, Deeva E, Yanvarev D, Ivanov A, Smirnova O, Kochetkov S, Chupakhin O, Kukhanova M. Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication. Antimicrob Agents Chemother. 2010 May;54(5):2017-22. doi: 10.1128/AAC.01186-09. Epub 2010 Mar 1. PMID: 20194696; PMCID: PMC2863629.
16: Loginova SIa, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, Charushin VN, Chupakhin ON. [Triazavirin prophylactic efficacy against influenza virus A (H5N1)]. Antibiot Khimioter. 2010;55(9-10):25-8. Russian. PMID: 21400750.
17: Lukovnikova LV, Sidorin GI, D’iakova LI, Skhodkina NI, Bitti MA, Cherkashchenko OS. [Basing approximate safe level of exposure to Triazavirin in air of workplace]. Med Tr Prom Ekol. 2009;(4):44-7. Russian. PMID: 19514171.
18: Loginova SIa, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, Charushin VN. [Investigation of triazavirin antiviral activity against influenza A virus (H5N1) in cell culture]. Antibiot Khimioter. 2007;52(11-12):18-20. Russian. PMID: 19275052.

Request a Quote